For: | Sun YL, Cai JQ, Liu F, Bi XY, Zhou LP, Zhao XH. Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer. World J Gastroenterol 2015; 21(38): 10840-10852 [PMID: 26478675 DOI: 10.3748/wjg.v21.i38.10840] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i38/10840.htm |
Number | Citing Articles |
1 |
Yameng Zhang, Yufei Gao, Youhe Gao. Early changes in the urine proteome in a rat liver tumour model. PeerJ 2020; 8: e8462 doi: 10.7717/peerj.8462
|
2 |
Fernanda Villarruel-Melquiades, María Eugenia Mendoza-Garrido, Claudia M García-Cuellar, Yesennia Sánchez-Pérez, Julio Isael Pérez-Carreón, Javier Camacho. Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma. World Journal of Gastroenterology 2023; 29(17): 2571-2599 doi: 10.3748/wjg.v29.i17.2571
|
3 |
Huan-Xi Li, Xiang-Yu Sun, Shi-Ming Yang, Qing Wang, Zhen-Yu Wang. Peroxiredoxin 1 promoted tumor metastasis and angiogenesis in colorectal cancer. Pathology - Research and Practice 2018; 214(5): 655 doi: 10.1016/j.prp.2018.03.026
|
4 |
Sangeeta Jaiswal, Bishnu Joshi, Jing Chen, Fa Wang, Michael K. Dame, Jason R. Spence, Gina M. Newsome, Erica L. Katz, Yatrik M. Shah, Sadeesh K. Ramakrishnan, Gaoming Li, Miki Lee, Henry D. Appelman, Rork Kuick, Thomas D. Wang. Membrane Bound Peroxiredoxin-1 Serves as a Biomarker for In Vivo Detection of Sessile Serrated Adenomas. Antioxidants & Redox Signaling 2022; 36(1-3): 39 doi: 10.1089/ars.2020.8244
|
5 |
Narumi OTSUKA, Kairi ISHIMARU, Mami MURAKAMI, Minami GOTO, Akihiro HIRATA, Hiroki SAKAI. The immunohistochemical detection of peroxiredoxin 1 and 2 in canine spontaneous vascular endothelial tumors. Journal of Veterinary Medical Science 2022; 84(7): 914 doi: 10.1292/jvms.22-0102
|
6 |
Hui Ma, Christine Loscher, Anne Parle-McDermott, Jenny Fitzgerald, Julie Meneely, Christopher Elliott, Richard Welten, Geofrey J. Mchau, Edna Makule, Revocatus Machunda, Yun Yun Gong, Martin Kimanya, Aoife Crawley, Ivan Maguire, Caroline Murphy, Richard O’Kennedy. Evaluation of a point-of-use device used for autoantibody analysis and its potential for following microcystin leucine-arginine exposure. Frontiers in Sensors 2024; 5 doi: 10.3389/fsens.2024.1302520
|
7 |
Meilin Ye, Ting Liu, Shanshan Liu, Rong Tang, Hongrui Liu, Fan Zhang, Shenglei Luo, Minqi Li. Peroxiredoxin 1 regulates crosstalk between pyroptosis and autophagy in oral squamous cell carcinoma leading to a potential pro-survival. Cell Death Discovery 2023; 9(1) doi: 10.1038/s41420-023-01720-7
|
8 |
Kun You, Peisheng Sun, Zhongyi Yue, Jian Li, Wancheng Xiong, Jianguo Wang. NOR1 promotes hepatocellular carcinoma cell proliferation and migration through modulating the Notch signaling pathway. Experimental Cell Research 2017; 352(2): 375 doi: 10.1016/j.yexcr.2017.02.032
|
9 |
Jie Zhao, Jinhui Guo, Yanan Wang, Qiancheng Ma, Yu Shi, Feng Cheng, Qiliang Lu, Wen Fu, Guangxiong Ouyang, Ji Zhang, Qiuran Xu, Xiaoge Hu. Research Progress of DUB Enzyme in Hepatocellular Carcinoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.920287
|
10 |
Chenbo Ding, Xiaobo Fan, Guoqiu Wu. Peroxiredoxin 1 – an antioxidant enzyme in cancer. Journal of Cellular and Molecular Medicine 2017; 21(1): 193 doi: 10.1111/jcmm.12955
|
11 |
Arianna Nicolussi, Sonia D'Inzeo, Carlo Capalbo, Giuseppe Giannini, Anna Coppa. The role of peroxiredoxins in cancer. Molecular and Clinical Oncology 2017; 6(2): 139 doi: 10.3892/mco.2017.1129
|
12 |
Qiongzhen Chen, Jinmeng Li, Xiaoning Yang, Junfeng Ma, Fanghua Gong, Yu Liu. Prdx1 promotes the loss of primary cilia in esophageal squamous cell carcinoma. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-06898-y
|
13 |
Gary A. Clawson, Gail L. Matters, Ping Xin, Christopher McGovern, Eric Wafula, Claude dePamphilis, Morgan Meckley, Joyce Wong, Luke Stewart, Christopher D’Jamoos, Naomi Altman, Yuka Imamura Kawasawa, Zhen Du, Loren Honaas, Thomas Abraham, Surinder K. Batra. "Stealth dissemination" of macrophage-tumor cell fusions cultured from blood of patients with pancreatic ductal adenocarcinoma. PLOS ONE 2017; 12(9): e0184451 doi: 10.1371/journal.pone.0184451
|
14 |
Yu Zhang, Xia‐Xin Wu, Shuang Li, Jin‐Feng Wu, Sen Han, Zhi‐Jie Lin, Shi‐Zhen Ding, Wei‐Juan Gong. Peroxiredoxin 1 as an inflammatory marker in diarrhea‐predominant and postinfectious irritable bowel syndrome. Neurogastroenterology & Motility 2020; 32(2) doi: 10.1111/nmo.13741
|
15 |
Yiqi Zhang, Kejia Wu, Yuxin Liu, Shuangling Sun, Yue Shao, Qingxiu Li, Xinying Sui, Changzhu Duan. UHRF2 promotes the malignancy of hepatocellular carcinoma by PARP1 mediated autophagy. Cellular Signalling 2023; 109: 110782 doi: 10.1016/j.cellsig.2023.110782
|
16 |
Lianxiang Luo, Xinyue Yao, Jing Xiang, Fangfang Huang, Hui Luo. Identification of ferroptosis-related genes for overall survival prediction in hepatocellular carcinoma. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-14554-7
|
17 |
Jan F. Stevens, Johana S. Revel, Claudia S. Maier. Mitochondria-Centric Review of Polyphenol Bioactivity in Cancer Models. Antioxidants & Redox Signaling 2018; 29(16): 1589 doi: 10.1089/ars.2017.7404
|
18 |
Zuzana Cockova, Hana Ujcikova, Petr Telensky, Jiri Novotny. Protein profiling of SH-SY5Y neuroblastoma cells: The effect of rhein. Journal of Biosciences 2019; 44(4) doi: 10.1007/s12038-019-9908-0
|
19 |
Junjun Zhang, Xi Zhang, Jie Li, Zewen Song. Systematic analysis of the ABC transporter family in hepatocellular carcinoma reveals the importance of ABCB6 in regulating ferroptosis. Life Sciences 2020; 257: 118131 doi: 10.1016/j.lfs.2020.118131
|
20 |
Bing Han, Hye-Jun Shin, In Seon Bak, Yesol Bak, Ye-Lin Jeong, Taeho Kwon, Young-Ho Park, Hu-Nan Sun, Cheol-Hee Kim, Dae-Yeul Yu. Peroxiredoxin I is important for cancer-cell survival in Ras-induced hepatic tumorigenesis. Oncotarget 2016; 7(42): 68044 doi: 10.18632/oncotarget.11172
|
21 |
Yao An, Jingwen Jiang, Li Zhou, Jinyu Shi, Ping Jin, Lei Li, Liyuan Peng, Siyu He, Wenhui Zhang, Canhua Huang, Bingwen Zou, Na Xie. Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma. Cancer Letters 2021; 521: 210 doi: 10.1016/j.canlet.2021.08.023
|